Non-small cell lung cancer (NSCLC) is frequently complicated by central nervous system (CNS) metastases affecting patients' life expectancy and quality. At the present clinical trials including neurosurgery, radiotherapy (RT) and systemic treatments alone or in combination have provided controversial ...
WX-0593 (Iruplinalkib) is a novel, highly selective oral ALK and ROS1 tyrosine kinase inhibitor (TKI). In this study, the safety, antitumor activity, and pharmacokinetics of WX-0593 were evaluated in advanced non-small cell lung cancer (NSCLC) patients w
1 (carcinoma, non small cell lung[MeSH Terms]) OR (carcinomas, non small cell lung[MeSH Terms])) OR (lung carcinoma, non small cell[MeSH Terms])) OR (lung carcinomas, non small cell[MeSH Terms])) OR (non small cell lung cancer[MeSH Terms])) OR (NSCLC[Title/Abstract]) 67,392 ...
Cell Mol Life Sci 74:4539–4560. https://doi.org/10.1007/s00018-017-2636-4 Article CAS PubMed PubMed Central Google Scholar Droege F, Thangavelu K, Stuck BA, Stang A, Lang S, Geisthoff U (2018) Life expectancy and comorbidities in patients with hereditary hemorrhagic telangiectasia. ...
Results published in theJournal of Thoracic Oncology, the official journal of the International Association for the Study of Lung Cancer (IASLC), show that the incremental cost-effectiveness ratio (ICER) for testing and waiting for results compared to treatment with chemotherapy with no testing was ...
It is known, however, that ALK gene rearrangements are common in inflammatory myofibroblastic tumors, similar to non-small cell lung cancer. In roughly 50% of inflammatory myofibroblastic tumors, gene rearrangement has been found to occur on chromosome 2 at band 2p23. In non-small cell lung ...
In this review, we underline the change in paradigm introduced by the ALK inhibitors in the treatment of advanced lung cancer positive for ALK as follows: In advanced ALK-positive NSCLC, the long expectancy of survival makes the ALK model unique; The treatment of intracranial disease is availab...